GLENMARK

Glenmark Pharmaceuticals Share Price

 

 

Invest in Glenmark Pharmaceuticals with 3.37X leverage

Invest with MTF

Performance

  • Low
  • ₹1,957
  • High
  • ₹1,988
  • 52 Week Low
  • ₹1,276
  • 52 Week High
  • ₹2,285
  • Open Price₹1,964
  • Previous Close₹1,974
  • Volume420,804

Investment Returns

  • Over 1 Month + 6.67%
  • Over 3 Month -1.14%
  • Over 6 Month + 30.1%
  • Over 1 Year + 27.09%

Smart Investing Starts Here Start SIP with Glenmark Pharmaceuticals for Steady Growth!

Invest Now

Glenmark Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 55
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 55,543
  • P/B Ratio
  • Average True Range
  • 44.97
  • EPS
  • 89.11
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 10.53
  • RSI
  • 62.05
  • MFI
  • 57.53

Glenmark Pharmaceuticals Financials

Glenmark Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,968.20
-5.6 (-0.28%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹1,915.13
  • 50 Day
  • ₹1,910.89
  • 100 Day
  • ₹1,889.16
  • 200 Day
  • ₹1,789.46

Resistance and Support

1971.07 Pivot Speed
  • R3 2,016.13
  • R2 2,002.07
  • R1 1,985.13
  • S1 1,954.13
  • S2 1,940.07
  • S3 1,923.13

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Glenmark Pharmaceuticals Ltd. is a global, research-driven pharmaceutical company with a focus on respiratory, dermatology, and oncology. It operates in over 80 countries with 10 manufacturing facilities, providing branded, generics, and specialty products to improve patient outcomes worldwide.

Glenmark Pharms. (Nse) has an operating revenue of Rs. 15,955.07 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 11% is healthy, ROE of 11% is good. The company has a reasonable debt to equity of 6%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 13% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 13% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 30 which is a POOR score indicating inconsistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Glenmark Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-09-26 Interim Dividend
2025-08-14 Quarterly Results
2025-05-23 Audited Results & Final Dividend
2025-02-14 Quarterly Results
Date Purpose Remarks
2025-10-03 INTERIM Rs.2.50 per share(250%)Interim Dividend
2025-09-15 FINAL Rs.2.50 per share(250%)Final Dividend
View Glenmark Pharmaceuticals Dividend History Arrow

Glenmark Pharmaceuticals F&O

Glenmark Pharmaceuticals Shareholding Pattern

46.65%
16.31%
0.66%
20.73%
0.02%
10.81%
4.82%

About Glenmark Pharmaceuticals

  • NSE Symbol
  • GLENMARK
  • BSE Symbol
  • 532296
  • Chairman & Managing Director
  • Mr. Glenn Saldanha
  • ISIN
  • INE935A01035

Similar Stocks to Glenmark Pharmaceuticals

Glenmark Pharmaceuticals FAQs

Glenmark Pharmaceuticals share price is ₹1,968 As on 05 December, 2025 | 21:03

The Market Cap of Glenmark Pharmaceuticals is ₹55542.8 Cr As on 05 December, 2025 | 21:03

The P/E ratio of Glenmark Pharmaceuticals is 55 As on 05 December, 2025 | 21:03

The PB ratio of Glenmark Pharmaceuticals is 6.3 As on 05 December, 2025 | 21:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23